In addition to traditional CV risk factors, proteinuria, and reduced GFR are significant predictors of CVD morbidity and mortality [27, 28]
Semaglutide's Cardiovascular Outcomes Trial Data The SUSTAIN-6 trial followed over 3,297 people with type 2 diabetes for more than three years and found that semaglutide reduced the combined risk of heart attack, stroke, and cardiovascular death by 26% compared to placebo
GLP-1 patches are marketed as alternatives to proven weight loss medications such as Mounjaro and Wegovy
Related Reading Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications Maximus Glp 1 Found Glp 1 Orderly Meds Glp 1 Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims
Originally developed to help people with type 2 diabetes , researchers noticed a significant side effect during trials: weight loss
Not. Grocery stores and major retailers